Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gemifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.93 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemifloxacin SCHEMBL29662144 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL13414391 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL2419850 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL136634 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL3252334 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL1444728 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL1950144 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL6930951 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL136633 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL1948042 | 0.99 | DPP4 (0.98) | DPP4CHRM2DRD1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10873 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-6340689-B1 | CONTACTING ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA, ESPECIALLY LEGIONELLA SPECIES, WITH ANTIBACTERIALLY EFFECTIVE AMOUNT OF COMPOSITION COMPRISING GEMIFLOXACIN COMPOUND OR ANTIBACTERIALLY EFFECTIVE DERIVATIVE THEREOF | SMITHKLINE BEECHAM CORPORATION | 2002-01-22 | — | — | US | claimed |
| US-6331550-B1 | MODULATING METABOLISM OF ANAEROBIC PATHOGENIC BACTERIA BY CONTACTING BACTERIA WITH ANTIBACTERIALLY EFFECTIVE AMOUNT OF COMPOSITION COMPRISING GEMIFLOXACIN COMPOUND OR DERIVATIVE | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | claimed |
| US-20010049378-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST MAXILLARY SINUS PATHOGENIC BACTERIA | LG LIFE SCIENCES LIMITED (KR) | 2001-12-06 | — | — | US | claimed |
| US-20010049366-A1 | Topical solution formulations containing an antibiotic and a corticosteroid | ALCON UNIVERSAL LTD. | 2001-12-06 | — | — | US | claimed |
| US-20010025048-A1 | Methods of use of antimicrobial compounds against pathogenic mycoplasma bacteria | SMITHKLINE BEECHAM CORPORATION | 2001-09-27 | — | — | US | claimed |
| US-6262071-B1 | ADMINISTERING A GEMIFLOXACIN COMPOUND, OR ANTIBACTERIALLY EFFECTIVE DERIVATIVES THEREOF. | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | claimed |
| WO-2001045679-A2 | USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT | SCHULZ HANS HERRMANN (DE) | 2001-06-28 | — | — | WO | claimed |
| WO-2001021176-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2001015695-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001000209-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-04 | — | — | WO | claimed |